CVS rallies on turnaround momentum and EPS growth, while CI is a defensive play with stable returns and a focused healthcare ...

Zacks highlights strong prospects for COST, CB, and CI, with Costco's steady growth, Chubb's strategic expansion, and Cigna's ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

This was the stock's second consecutive day of losses.

Cigna Group’s drug benefit unit is offering a new way for health plans to cover expensive weight-loss drugs that it says will ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

On Friday, May 23, UBS analyst AJ Rice reaffirmed a “Buy” rating on The Cigna Group (NYSE: CI) with a price target of $390.

Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

Grow Therapy, a hybrid mental health provider, has launched a new care coordination program to streamline provider referrals ...

Cigna on Friday raised its full-year earnings forecast and beat estimates for quarterly profit, helped by strong performance in its pharmacy benefit management business and lower-than-expected medical ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...